MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.3 -0.76

Buy Sell

Overview

Share price change

24h

Current

Min

1.29

Max

1.32

Key metrics
By Trading Economics
Income	2.7M -24M
EPS	-0.354
Employees	49
EBITDA	-5.3M -28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+105.38% upside

Dividends
By Dow Jones
Next Earnings	7 May 2026

Market Stats
By TradingEconomics
Market Cap	-624K 80M
Previous open	2.06
Previous close	1.3

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Apr 2026, 23:26 UTC

Hot Stocks

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 Apr 2026, 20:41 UTC

Major Market Movers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 Apr 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 Apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16 Apr 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 Apr 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 Apr 2026, 22:08 UTC

Earnings

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 Apr 2026, 22:06 UTC

Earnings

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 Apr 2026, 22:06 UTC

Earnings

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 Apr 2026, 22:06 UTC

Earnings

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 Apr 2026, 22:06 UTC

Earnings

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 Apr 2026, 22:06 UTC

Earnings

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 Apr 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

16 Apr 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Apr 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

16 Apr 2026, 20:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

16 Apr 2026, 20:49 UTC

Earnings

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 Apr 2026, 20:43 UTC

Earnings

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 Apr 2026, 20:40 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

16 Apr 2026, 20:40 UTC

Market Talk

Earnings

Netflix Says Engagement Quality Hits New High -- Market Talk

16 Apr 2026, 20:30 UTC

Hot Stocks

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 Apr 2026, 20:25 UTC

Earnings

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 Apr 2026, 20:23 UTC

Earnings

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 Apr 2026, 20:19 UTC

Earnings

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 Apr 2026, 20:17 UTC

Earnings

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 Apr 2026, 20:17 UTC

Earnings

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 Apr 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 Apr 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 Apr 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 Apr 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

105.38% upside

12 Months Forecast

Average 2.67 USD 105.38%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.